Xspray Pharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was SEK 51.4 million compared to SEK 28.87 million a year ago. Basic loss per share from continuing operations was SEK 2.27 compared to SEK 1.4 a year ago. Diluted loss per share from continuing operations was SEK 2.27 compared to SEK 1.4 a year ago.
For the six months, net loss was SEK 86.23 million compared to SEK 47.8 million a year ago. Basic loss per share from continuing operations was SEK 3.8 compared to SEK 2.31 a year ago. Diluted loss per share from continuing operations was SEK 3.8 compared to SEK 2.31 a year ago.